David R. Craig, MBA

David R. Craig, MBA

Springfield, Massachusetts, United States
5K followers 500+ connections

Join to follow

About

With a foundation as CEO of Sarcomatrix, my journey in the biotech sector is defined by a…

Services

Request proposal

Articles by David R.

Contributions

Join now to see all contributions

Activity

Join now to see all activity

Experience

  • Sarcomatrix Graphic

    Sarcomatrix

    Reno, Nevada, United States

  • -

  • -

    San Francisco Bay Area

  • -

  • -

  • -

    Boston, Massachusetts, United States

  • -

    South San Francisco, California, United States

  • -

    San Francisco Bay Area

  • -

    Redwood City, CA

  • -

    Mountain View, CA

  • -

    Los Altos, CA

  • -

    Palo Alto, California, United States

  • -

    Foster City, California, United States

  • -

    San Francisco, California, United States

  • -

    United States

Education

  • Pepperdine Graziadio Business School Graphic

    Pepperdine Graziadio Business School

  • Activities and Societies: Cum Laude

    South Dakota State University’s School of Pharmacy and Allied Health Professions has been ranked #3 in the nation, a testament to its excellence in education, research, and clinical training. This achievement highlights the school's commitment to preparing top-tier professionals in the pharmaceutical sciences. #PharmacyExcellence #SDSU #TopRanked

Licenses & Certifications

Volunteer Experience

  • Executive Board Member

    South Lake Tahoe Amateur Hockey Association

    - Present 13 years

  • Bullpen Graphic

    Founding Member

    Bullpen

    - Present 1 year 2 months

    Science and Technology

    The Bullpen is an invite-only, volunteer-led Club that gathers Life Science Investors and CEOs with a shared goal of helping each other.

Publications

  • Sunitinib promotes myogenic regeneration and mitigates disease progression in the mdx mouse model of Duchenne muscular dystrophy

    1Department of Pharmacology, University of Nevada, Reno School of Medicine, , Reno, NV 89557, USA and 2Division of Pre-clinical Innovation, NIH Center for Advancing Translational Sciences, Rockville, MD 20850, USA

    Abstract
    Duchenne muscular dystrophy (DMD) is a lethal,muscle degenerative disease causing premature death of affected children. DMD is characterized by mutations in the dystrophin gene that result in a loss of the dystrophin protein. Loss of dystrophin causes an associated reduction in proteins of the dystrophin glycoprotein complex, leading to contraction-induced sarcolemmal weakening,muscle tearing, fibrotic infiltration and rounds of degeneration and failed regeneration affecting…

    Abstract
    Duchenne muscular dystrophy (DMD) is a lethal,muscle degenerative disease causing premature death of affected children. DMD is characterized by mutations in the dystrophin gene that result in a loss of the dystrophin protein. Loss of dystrophin causes an associated reduction in proteins of the dystrophin glycoprotein complex, leading to contraction-induced sarcolemmal weakening,muscle tearing, fibrotic infiltration and rounds of degeneration and failed regeneration affecting satellite cell populations. The α7β1 integrin has been implicated in increasing myogenic capacity of satellite cells, therefore restoring muscle viability, increasing muscle force and preserving muscle function in dystrophic mouse models. In this study, we show that a Food and Drug Administration (FDA)-approved small molecule, Sunitinib, is a potent α7 integrin enhancer capable of promoting myogenic regeneration by stimulating satellite cell activation and increasing myofiber fusion. Sunitinib exerts its regenerative effects via transient inhibition of SHP-2 and subsequent activation of the STAT3 pathway. Treatment of mdx mice with Sunitinib demonstrated decreased membrane leakiness and damage owing to myofiber regeneration and enhanced support at the extracellular matrix. The decreased myofiber damage translated into a significant increase in muscle force production. This study identifies an already FDA-approved compound, Sunitinib, as a possible DMD therapeutic with the potential to treat other muscular dystrophies in which there is defective muscle repair.

    See publication

Courses

  • Certified Blockchain & Healthcare Professional(TM)

    Certificate ID 48083297

  • Certified Coding Professional

    -

  • Lean Six Sigma Green Belt

    5000

  • Project Management Professional

    -

Honors & Awards

  • Mortar Board Honor Society

    Mortar Board National College Senior Honor Society

Languages

  • English

    Full professional proficiency

Recommendations received

2 people have recommended David R.

Join now to view

More activity by David R.

View David R.’s full profile

  • See who you know in common
  • Get introduced
  • Contact David R. directly
Join to view full profile

Other similar profiles

Explore collaborative articles

We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.

Explore More

Add new skills with these courses

See all courses